You are here: Industry Insights > Immunotherapeutics

News List

OSE Immunotherapeutics Announces Positive Results from Antagonist OSE-127 Study americanpharmaceuticalreview
December 30, 2019
OSE Immunotherapeutics announced completion and positive results from the Phase 1 study of OSE-127, a humanized monoclonal antibody with a differentiated mechanism of action ...
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors drugs
June 19, 2019
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors.
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics en-cphi.cn
December 10, 2018
WuXi Biologics announces a strategic collaboration with Brii Biosciences.
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics pharmafocusasia
November 12, 2018
IRX Therapeutics, Inc. today announced that the company’s assets have been acquired by the newly formed Brooklyn ImmunoTherapeutics LLC. This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a
Selexis SA and OSE Immunotherapeutics Enter Pact contractpharma
May 26, 2017
Selexis SA and OSE Immunotherapeutics SA have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform.